Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte (INCY), MorphoSys Win EC Approval for Lymphoma Drug
12:18pm, Friday, 27'th Aug 2021
Incyte (INCY) and partner MorphoSys obtain approval for tafasitamab for adult patients with relapsed or refractory diffuse large B-cell lymphoma by the European Commission.
Incyte - MorphoSys's Diffuse Large B-Cell Lymphoma Drug Wins European Approval
06:19am, Friday, 27'th Aug 2021
The European Commission (EC) has granted conditional approval to Incyte Corporation (NASDAQ: INCY) - MorphoSys AG's (NASDAQ: MOR) Minjuvi (tafasitamab) for relapsed or refractory diffuse large B
Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China
06:37am, Tuesday, 17'th Aug 2021
Incyte Corporation (NASDAQ: INCY) and InnoCare have entered into a collaboration and license agreement to develop and commercial tafasitamab in Greater China. Under the terms of the agreement, In
Incyte: Undervalued And Expecting FDA Feedback In H2 2021
04:08pm, Sunday, 15'th Aug 2021
Incyte Corp is a biopharmaceutical company conducting both commercial and clinical development operations.
Is the PD-(L)1 Party Over After Incyte's FDA Rejection?
08:01am, Saturday, 07'th Aug 2021
There's definitely already a crowded market for PD-1 and PD-L1 immunotherapies.
4 Bullish Stock Picks After Earnings With Huge Potential Upside
11:12am, Thursday, 05'th Aug 2021
Earnings season is winding down. With that come analyst projections for where these stocks and the market in general could go in the coming months.
Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q2 2021 Results - Earnings Call Transcript
01:29pm, Tuesday, 03'rd Aug 2021
Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q2 2021 Results - Earnings Call Transcript
A Preview Of Incyte's Earnings
10:58am, Monday, 02'nd Aug 2021
Incyte (NASDAQ:INCY) will be releasing its next round of earnings this Tuesday, August 03. For all of the relevant information, here is your guide for Tuesday's Q2 earnings announcement.
2 Stocks Under $100 You Can Buy and Hold Forever
08:38am, Saturday, 31'st Jul 2021
Drugmakers can be excellent long-term holdings.
Incyte (INCY) to Post Q2 Earnings: Will Jakafi Sales Disappoint?
11:25am, Wednesday, 28'th Jul 2021
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports second-quarter 2021 results.
FDA Strikes Off Incyte's Retifanlimab Application In Anal Cancer
06:29am, Monday, 26'th Jul 2021
The FDA has issued a Complete Response Letter (CRL) to Incyte Corporation (NASDAQ:INCY) marketing application seeking approval for retifanlimab in anal cancer. The application covers adult patient
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
REGN or INCY: Which Is the Better Value Stock Right Now?
12:59pm, Thursday, 22'nd Jul 2021
REGN vs. INCY: Which Stock Is the Better Value Option?
Benchmark Upgrades Incyte After Stock Selloff
03:28pm, Tuesday, 20'th Jul 2021
The recent downturn in Incyte Corporation's (NASDAQ:INCY) share price offers an entry opportunity, with the FDA likely to approve ruxolitinib in chronic GVHD indication in September 2021, according to
Lilly (LLY), Incyte's Decision on Olumiant sNDA Delayed by FDA
12:13pm, Monday, 19'th Jul 2021
The FDA will not meet the PDUFA action date for Lilly (LLY) and Incyte's (INCY) sNDA for Olumaint to treat adults with atopic dermatitis.
